Viking Therapeutics (STU:1VT) Cyclically Adjusted Book per Share: €3.47 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1VT Viking Therapeutics Inc STU:1VT
38 GF Score
Price €29.00
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Cyclically Adjusted Book per Share?

Viking Therapeutics STU:1VT -2.36% 38 Cyclically Adjusted Book per Share is €3.47 as of Mar. 2026. GuruFocus rates STU:1VT with a GF Score™ of 38/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Viking Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €3.746. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.47 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Viking Therapeutics's average Cyclically Adjusted Book Growth Rate was 22.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 27.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Viking Therapeutics was 27.70% per year. The lowest was 27.70% per year. And the median was 27.70% per year.

As of today (2026-07-30), Viking Therapeutics's current stock price is €29.00. Viking Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €3.47. Viking Therapeutics's Cyclically Adjusted PB Ratio of today is 8.36.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Viking Therapeutics was 8.33. The lowest was 0.00. And the median was 0.00.


Viking Therapeutics  (STU:1VT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Viking Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=29.00/3.47
=8.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Viking Therapeutics was 8.33. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Viking Therapeutics Cyclically Adjusted Book per Share Related Terms


Viking Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Cyclically Adjusted Book per Share Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.68 1.98 3.02 3.36

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.20 3.10 3.12 3.36 3.47

STU:1VT vs DYN, CELC, RLAY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Viking Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viking Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:1VT
38GF Score
Viking Therapeutics Inc STU:1VT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viking Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.746/330.2130*330.2130
=3.746

Current CPI (Mar. 2026) = 330.2130.

Viking Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.590 241.018 0.808
201609 0.458 241.428 0.626
201612 0.366 241.432 0.501
201703 0.295 243.801 0.400
201706 0.212 244.955 0.286
201709 0.066 246.819 0.088
201712 0.318 246.524 0.426
201803 1.157 249.554 1.531
201806 1.981 251.989 2.596
201809 3.631 252.439 4.750
201812 3.648 251.233 4.795
201903 3.619 254.202 4.701
201906 3.536 256.143 4.559
201909 3.562 256.759 4.581
201912 3.444 256.974 4.426
202003 3.346 258.115 4.281
202006 3.197 257.797 4.095
202009 2.955 260.280 3.749
202012 2.743 260.474 3.477
202103 2.582 264.877 3.219
202106 2.388 271.696 2.902
202109 2.315 274.310 2.787
202112 2.283 278.802 2.704
202203 2.139 287.504 2.457
202206 2.038 296.311 2.271
202209 1.992 296.808 2.216
202212 1.753 296.797 1.950
202303 1.579 301.836 1.727
202306 3.563 305.109 3.856
202309 3.449 307.789 3.700
202312 3.191 306.746 3.435
202403 7.795 312.332 8.241
202406 7.722 314.175 8.116
202409 7.369 315.301 7.718
202412 7.535 315.605 7.884
202503 6.977 319.799 7.204
202506 6.140 322.561 6.286
202509 5.403 324.800 5.493
202512 4.754 324.054 4.844
202603 3.746 330.213 3.746

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €3.47 mean?
Viking Therapeutics (STU:1VT) has a Cyclically Adjusted Book per Share of €3.47 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Viking Therapeutics and its competitors.
Is Viking Therapeutics' Cyclically Adjusted Book per Share too high?
Viking Therapeutics' current Cyclically Adjusted Book per Share is €3.47. Overall, Viking Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Cyclically Adjusted Book per Share compare to DYN and CELC?
Viking Therapeutics' Cyclically Adjusted Book per Share of €3.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current Cyclically Adjusted Book per Share is €3.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (STU:1VT) has a current Cyclically Adjusted Book per Share of €3.47. The current Cyclically Adjusted Book per Share is €3.47. Viking Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Viking Therapeutics (STU:1VT), the current Cyclically Adjusted Book per Share is €3.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Other Exchanges VKTX:USA1VKTX:Italy0VQA:UK
Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
38GF Score

Get the complete analysis for STU:1VT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.00
Price